Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 8/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3849395 | 0.87 | DRD2 (0.45) | MTNR1AMTNR1BCNR2CA1CA2 | |
| SCHEMBL3850247 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BCNR2CA1CA2 | |
| SCHEMBL3858044 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BCNR2CA1CA2 | |
| SCHEMBL3851046 | 0.83 | MTNR1A (0.48) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL3973524 | 0.80 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL11040374 | 0.75 | MTNR1A (0.61) | MTNR1AMTNR1BCNR2CA1CA2 | |
| SCHEMBL3848346 | 0.75 | MTNR1A (0.61) | MTNR1AMTNR1BCNR2CA1CA2 | |
| SCHEMBL3848918 | 0.73 | MTNR1A (0.59) | MTNR1AMTNR1BCNR2CA1CA2 | |
| SCHEMBL3978300 | 0.73 | SIGMAR1 (0.38) | ACHE | |
| SCHEMBL3974229 | 0.72 | CA1 (0.51) | MTNR1AMTNR1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | ZHAN-PLASKET FAN | 2009-12-31 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| EP-1745016-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105737-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-10 | — | — | WO | disclosed |
| US-20050240049-A1 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | TDO2, ITPA, TTI2 | MTNR1A 4194/4885MTNR1B 3845/4885CNR2 2775/4885 |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | TDO2, ITPA, TTI2 | MTNR1A 4194/4885MTNR1B 3845/4885CNR2 2775/4885 |
| US-20050240049-A1 | Process for the preparation of substituted tetralin and substituted indane derivatives | TDO2, TTI2, ITPA | MTNR1A 4200/4885MTNR1B 3824/4885CNR2 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.